Primary and secondary immune checkpoint inhibitors resistance in colorectal cancer: Key mechanisms and ways to overcome resistance
Immune checkpoint inhibitors (ICIs) have significantly advanced colorectal cancer treatment in recent years. Antibodies that target the proteins programmed cell death-1 (PD-1), programmed cell death-1 ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) are among the ICIs that...
Main Authors: | Hassan Abushukair, Obada Ababneh, Sara Zaitoun, Anwaar Saeed |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-01-01
|
Series: | Cancer Treatment and Research Communications |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2468294222001344 |
Similar Items
-
Genomic and Transcriptomic Predictors of Response to Immune Checkpoint Inhibitors in Melanoma Patients: A Machine Learning Approach
by: Yaman B. Ahmed, et al.
Published: (2022-11-01) -
Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities
by: Qingqing Xie, et al.
Published: (2022-09-01) -
Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade
by: Jun Gong, et al.
Published: (2018-10-01) -
Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer
by: Chang Woo Kim, et al.
Published: (2021-09-01) -
Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer
by: Rui He, et al.
Published: (2021-11-01)